As the mobility industry waits with baited breath to see how Uber’s IPO will play out on Friday, there is plenty of news being made elsewhere in the sector. Cruise scored another massive investment, Toyota AI Ventures opened a new fund,... Read more »
Open source website software company Acquia is buying marketing automation startup Mautic, the companies said. Terms of the deal were not disclosed.
Acquia, based in Boston, develops open source tools to manage websites built using the open source content management system... Read more »
Goldfinch Bio set out to build a database of patients with kidney diseases, which it could study to understand the biology and genetics of kidney disorders in order to develop better drugs. The biotech startup is making headway on its research... Read more »
Newly public ride-hailing company Lyft (NASDAQ: LYFT) filed its first-quarter earnings results Tuesday, reporting a 95 percent increase in revenue compared with the same period in 2018, but a net loss of nearly $1.14 billion.
That first-quarter loss includes $894 million... Read more »
The American Academy of Neurology meeting in Philadelphia is rolling on through the end of this week. There has been plenty of news to digest already. New clinical data could herald cutting-edge treatments for migraine, the rare disease spinal muscular atrophy,... Read more »
Women hold a small fraction of venture capital leadership roles in the US and Canada. A new report suggests their clearest path to venture investing may run through corporate innovation arms.
While only 15.9 percent of corporate venture capital (CVC) leaders... Read more »
Landing its second shot of new capital in less than a year, cybersecurity startup Exabeam announced today it secured $75 million in a Series E funding round co-led by new investor Sapphire Ventures and returning investor Lightspeed Venture Partners.
San Mateo,... Read more »
A new startup wants to edit out the world’s biggest killer. Prominent cardiologist and geneticist Sekar Kathiresan is heading up a new company, Verve Therapeutics, that will develop gene-altering medicine to prevent heart attacks. Heart disease is the leading cause of... Read more »
[Updated 5/6/19, 9:20 am ET. See below.] A year ago, there were no FDA-approved medicines available for US patients with the debilitating rare genetic disease transthyretin amyloidosis (ATTR). Things have changed fast, however: With the FDA’s decision to approve... Read more »